| Home | E-Submission | Sitemap | Contact Us |  
top_img
Cancer Research and Treatment > Accepted Articles
doi: https://doi.org/10.4143/crt.2024.008    [Accepted]
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
Youjin Kim1 , Bhumsuk Keam2,3 , Eun Joo Kang4, Jin-Soo Kim5, Hye Ryun Kim6, Keun-Wook Lee7, Jung Hye Kwon8, Kyoung Eun Lee9, Yaewon Yang10, Yoon Hee Choi11, Min Kyoung Kim12, Jun Ho Ji13, Tak Yun14, Moon Young Choi15, Ki Hyeong Lee10, Sung-Bae Kim16, Myung-Ju Ahn17
1Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
2Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
3Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
4Division of Hematology-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
5Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea
6Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
7Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
8Division of Hematology-Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
9Department of Internal Medicine, Ewha Womans University Medical Center, Seoul, Korea
10Department of Internal Medicine, Chungbuk University Hospital, Chungbuk University College of Medicine, Cheongju, Korea
11Division of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea
12Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea
13Division of Hematology-Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
14Rare Cancers Clinic, Center for Specific Organs Cancer, National Cancer Center, Goyang, Korea
15Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
16Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
17Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence  Bhumsuk Keam ,Tel: 82-2-2072-7215, Fax: 82-2-2072-7379 , Email: bhumsuk@snu.ac.kr
Received: January 2, 2024;  Accepted: April 14, 2024.  Published online: April 15, 2024.
ABSTRACT
Purpose
In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Materials and Methods
We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.
Results
In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and 3 patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6, 12.4, and 18.1 months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.
Conclusion
Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
Key words: Adenoid cystic carcinoma, Tyrosine kinase inhibitors, Vascular endothelial growth factor receptor, Axitinib, Nintedanib
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Share:      
METRICS
0
Crossref
0
Scopus
497
View
39
Download
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI